(1) Stimulation of CLL tumor cells by type 1 interferon (IFN) or toll-like receptor (TLR) ligands can drive NF-κB–dependent expression of the T-bet transcription factor. (2) This leads to enhanced interferon signaling and reduced tumor cell proliferation. (3) Tumors that have higher levels of T-bet at diagnosis are associated with longer patient survival.